A recent report, which suggested that AURKB inhibition by barasertib stabilizes TP53 in breast cancer [19], led us to hypothesize that the sensitivity to AURKB inhibition in MNA NB cells is mediated by intact TP53 activity. The gene discussed is TP53; the disease is breast cancer.